• Target disease: Chagas
  • Main partners (since project start): AbbVie, USA; AstraZeneca, UK; Brazilian Biosciences National Laboratory, Brazil; Centre for Drug Candidate Optimization, Monash University, Australia; Drug Discovery Unit, University of Dundee, UK; Epichem, Australia; Eisai Co., Ltd., Japan; Griffith Institute for Drug Discovery (formerly Eskitis Institute for Cell and Molecular Therapies), Australia; Fundaçao de Apoio Universidade Federale de Sao Paolo, Brazil; GlaxoSmithKline, UK; Griffith University, Australia; Laboratory of Microbiology, Parasitology and Hygiene, University of Antwerp, Belgium; Institut Pasteur Korea, South Korea; London School of Hygiene & Tropical Medicine, UK; Merck, USA; Shionogi & Co., Ltd., Japan; Sanofi, France; Sandexis, UK; Takeda Pharmaceutical Company Ltd., Japan; The Swiss Tropical and Public Health Institute, Switzerland; TCG Life Sciences, India; Instituto de Física, Universidad Sao Paolo, Brazil; Instituto de Química, University Estadual of Campinas, Brazil; WuXi AppTech, China.
  • Project start: Ongoing
  • Funding (since project start): Australian Research Council (ARC), Australia; Department for International Development (DFID), UK; Médecins Sans Frontières/Doctors without Borders, International; Ministry of Health, Brazil.


Overall objective:

  • Through collaborative hit-to-lead projects, identify new leads with activity in animal models of disease and the potential for further optimization


Multiple hits from screening with several pharmaceutical partners or from other sources have progressed into hit confirmation and expansion studies. Opportunities for new candidates to include in the pipeline are continually under review. Preliminary mapping and set-up of discovery activities are continuing in Latin America in accordance with the global DNDi strategy of empowerment of, and funding from, the regional offices.


DNDi has continued its efforts in screening chemically diverse libraries for identification and confirmation of new hits that could progress and feed the hit-to-lead pipeline. In 2018, a new partnership was established with the Drug Discovery Unit from Dundee University in Scotland and GSK to jointly characterize and progress new promising hits.

A new discovery cascade has been implemented comprising new in vitro and in vivo If promising activity is demonstrated, the identified series would then be advanced into full lead optimization programmes.

Last update: August 2019